Skip to main content

Table 1 Flow of patients through the study (inclusion criteria)

From: Association of CYP2D6metabolizer status with mammographic density change in response to tamoxifen treatment

  n
Genotyped 710
Overlap with women with mammograms retrieved 570
Nonmissing date of initiation of tamoxifen therapy 562
Duration of treatment ≥6 months 530
Complete set of baseline and follow-up mammograms 309
Postmenopausal at baseline 308
Genotyped from blood 278
Baseline percent mammographic density (PMD) ≥10% 186